In my three decades treating addiction, few questions have come up more often in the past year than this one: "Why did my drinking fall off after I started Ozempic?" Patients notice it before anyone tells them to expect it. The urge simply gets quieter, and they want to know why.
That observation has now been repeated in enough research to take seriously. Human studies have shown that GLP-1 drugs reduce alcohol consumption, and a Lancet trial earlier this year found semaglutide cut heavy drinking days by 41 percent in people with alcohol use disorder. Preclinical animal studies have extended the effect to cocaine, amphetamines, opioids, and nicotine. So the question was never whether these medications quiet craving. The question was how, and until recently nobody had a good answer.
The obvious suspects did not fit. The brain regions we normally associate with reward, the ventral tegmental area and the nucleus accumbens, produce and receive the dopamine surges that addictive drugs hijack. But those regions carry very few GLP-1 receptors, which means a drug that mimics the GLP-1 hormone has no direct way to act on them. Whatever these medications were doing to craving, they were doing it somewhere else.
Researchers now believe they have found that somewhere. It is a small structure called the lateral septum, and the case for it has grown strong enough that Robert Munn, a researcher at the University of Otago who studies this region, recently wrote that the findings have put the spotlight firmly on the lateral septum as the home of cravings.
The Brain Region Almost Nobody Was Watching
The lateral septum sits deep in the middle of the brain, one connection upstream from the dopamine system. For decades it was known mostly for a strange finding from 1953, when researchers Joseph Brady and Walle Nauta observed that animals with damage to this region became intensely aggressive, a phenomenon they called septal rage. After that, the region faded into the background of neuroscience while the spotlight stayed on dopamine.
Recent work has changed that. The lateral septum receives its main input from the hippocampus, the structure that builds our episodic memories and tracks where we are in space and time. The hippocampus sends the lateral septum a running record of place and moment, and the lateral septum adds something to it. Research published in eLife has shown that the lateral septum contains place cells of its own, and that these cells respond strongly to rewards. In plain terms, the hippocampus says "here is where you are," and the lateral septum answers "and here is what felt good in this place." That combined signal then travels onward to the dopamine system.
This is the anatomy of a trigger. Anyone who has lived with addiction, or loved someone who has, knows that craving rarely announces itself at random. It arrives with a place, a time of day, a payday, a particular corner, a certain group of friends. The lateral septum is where that binding of memory, context, and reward appears to happen, and it turns out to be loaded with GLP-1 receptors.
The Circuit That Puts a Brake on Reward
The strongest evidence arrived earlier this year in the journal Neuron. A team led by Yingjie Zhu and Zijun Chen at the Shenzhen Institute of Advanced Technology of the Chinese Academy of Sciences mapped, in mice, exactly how the GLP-1 drug liraglutide suppresses drinking. The drug activates GLP-1 receptor neurons in the dorsal part of the lateral septum. Those neurons then inhibit a second population of neurons in the ventral part, cells that normally project to the ventral tegmental area and promote dopamine release when alcohol is on board. The result is a braking circuit: when the GLP-1 neurons fire, alcohol-induced dopamine release drops, and the animals drink less.
A separate rodent study in eBioMedicine reached the same destination from a different direction. When researchers infused a GLP-1 receptor agonist directly into the lateral septum, alcohol intake fell in a dose-dependent way, and food and water intake did not change. When they blocked the same receptors, drinking increased. My reading of that second finding is that this circuit may be more than a drug target, because a system that increases drinking when you block it looks like a brake the brain is already using. The same study also reported that receptor levels in this region correlated with how much the male rats drank but not the females, a sex difference the field has yet to explain.
Munn's own laboratory has added a third line of evidence, showing in rats that liraglutide changes the electrical rhythms of the lateral septum in ways that may weaken its communication with the rest of the reward system. His group's work is still in preprint, and the whole picture so far rests on rodent studies, so there is real distance between these findings and a clinical protocol. But three independent research groups have now converged on the same small structure, and that convergence is what makes this story worth telling.
What This Means for Recovery
I have spent much of my career explaining to patients and families that craving is not a character flaw. Brain imaging work, including a meta-analysis showing the same reward-circuit disruption across nine different addictions, has made that case at the level of anatomy. The lateral septum research adds something more precise: craving may have an address, a place where memory and context are converted into the felt pressure to use. If that holds up, it explains why willpower alone tends to fail at the exact moments when the environment is saturated with cues, and why so many people in early recovery describe being ambushed by an urge they did not see coming.
It also matters for treatment. GLP-1 medications are not approved for addiction, and the clinical trials that would support that use are still underway, so no one should start one of these drugs expecting a cure for craving. But if you are in recovery and already have a medical reason to consider a GLP-1 medication, such as diabetes or obesity, this research is worth a conversation with your physician, because the drug you take for your metabolism may also be acting on the circuit that drives your urges. At Rescue From Rehab we build recovery plans around exactly this kind of neurobiology, because treating addiction without attending to the brain circuits that sustain it is treating half the illness.
For years, people in recovery have been told their cravings were a failure of commitment. The science keeps saying otherwise. Craving is circuitry, the circuitry is being mapped, and every map like this one moves treatment closer to the dignity of any other medical care.